Top Stories

Abbott India Q1 Results: Net profit rises 41.2% to Rs 290.20 crore

Aug 10, 2023

By: BlinkX Research Team

The pharmaceutical company's net profit for the June quarter increased significantly by 41.2%, from Rs 205.60 crore in the base period to Rs 290.20 crore.

Strong sales helped the bottom line rise as revenue increased 13.4% YoY to Rs 1,479 crore.

The majority of Abbott India's income comes from its core pharmaceutical business. In India, the company is involved in the creation and marketing of approximately 600 goods, including vitamins, allergy medications, and consumer care items.

On the strength of decreasing expenditures and sustained sales, the company has also continuously maintained double-digit revenue growth over the last three quarters.

In April - June, the company's EBITDA margin increased significantly to 24% from 20.7% in the same period of the previous year.

The company's earnings profile has steadily improved over the last several quarters as a result of its five-year compounded sales and profit growth of 10% and 19%, respectively. The company has a solid track record for return on equity (ROE), having produced a RoE of about 30% during the previous three years.

Source: Media Reports